###### What are the new findings?

1.  The stress test presented here is suitable to evaluate muscular changes and may be used to analyse joint metabolism, even in elderly with healthy joints.

2.  Pronounced training effects could be observed by moderate training with the Nintendo Wii performed three times a week for 30 min in an elderly population.

3.  A supplementation with branched-chain amino acid that is rich in leucine can reduce exercise-induced strength loss and may contribute indirectly to the protection of the joint complex.

Introduction {#s1}
============

Age-related muscle loss is characterised by a progressing decrease in muscle mass, strength and function. Beginning in the mid-1930s, 3%--8% of the body's skeletal muscle mass may be lost per decade, and this loss rate even accelerates after the age of 60.[@R1] This continuous decline in muscle mass is accompanied by impaired mobility and, consequently, decreased physical activity. Impaired mobility has a medical impact, such as increased risk for falls and fractures, increased morbidity, loss of independence, depression and other adverse consequences, and is linked to the loss of quality of life. Interestingly enough, people do not link the loss of mobility to the loss of muscle mass and therefore do not take action for prevention. It is plausible that decreased physical mobility is caused by muscle atrophy and indirectly by decreased joint stability due to sarcopenia in the joint-surrounding muscles. A loss of muscle strength therefore results in a decreased protection of the affected joints from physical stress and a higher risk of joint overload and concomitant disturbance of cartilage homeostasis. As cartilage homeostasis is influenced by ageing anyway,[@R2] loss of muscular protection could have an additional negative effect on joint health, which could lead to an earlier overturn of balance. The complex process of age-related muscle loss is facilitated by multiple factors, including less activity, missing training and a suboptimal diet.[@R3]

Although the mechanisms leading to age-related muscle loss are likely numerous, a disproportionate ratio of muscle protein breakdown compared with muscle protein synthesis is believed to have high relevance. There is evidence that an increased availability of protein or amino acids can shift the metabolism towards anabolism and particularly enhance muscle protein synthesis in young and older subjects.[@R4] Branched-chain amino acids (BCAAs), leucine in particular, may be responsible for the amino-acid-induced stimulation of muscle protein synthesis.[@R1] Leucine appears to play a key role in the regulation of muscle protein synthesis,[@R5] and most notable effects on amino -acid metabolism in the skeletal muscle have been observed for leucine.[@R6] One site for leucine action is a kinase in the insulin signalling cascade previously identified as the mammalian target of rapamycin (mTOR), which has a central role in the regulation of protein synthesis. Leucine also stimulates activation of a second initiation factor eukaryotic initiation factor 4G through an mTOR-independent kinase.[@R6] Additionally, leucine seems to play a role in decreasing the protein degradation rate.[@R5] Strength training and activity are very important in preventing age-related muscle loss due to its influence on muscle mass and protein synthesis.[@R1] For initiation of muscle protein synthesis and hypertrophy, a complementary, appropriate nutrition that is rich in protein, especially BCAAs, is also important to support training effects and may positively influence the protein synthesis to protein degradation ratio.[@R1] The whole-body protein synthesis declines from birth to old age.[@R9] High-protein meals have been shown not to enhance the myofibrillar synthesis[@R10] but amino acids alone to stimulate muscle protein anabolism in younger and older people[@R11]. As skeletal muscle mass is responsive to changes in physical activity, reduced activity in older people participates to the complex progress of sarcopenia.[@R13] If exercise, which positively influences protein homeostasis, is combined with an increased uptake of BCAAs, especially leucine, it could be beneficial in maintaining muscle mass and muscle function and prevent sarcopenia.

Little and Phillips proposed three stimulants of protein synthesis: Leucine, Insulin and resistance training.[@R14] A combination of resistance exercise with dietary intake of leucine-enriched amino acids should therefore present the most effective strategy to promote a beneficial relation between protein synthesis and degradation. Due to the role of leucine in the protein synthesis pathway and the muscle degradation mechanism, the focus of interest lies in its influence on muscle building and in its potential for supporting regeneration. The purpose of this study was to evaluate the effect of a 12-week leucine-rich amino acid supplementation in combination with moderate training in elderly participants.

Materials and methods {#s2}
=====================

Study design {#s2a}
------------

The study was a monocentre, randomised, double-blind, placebo-controlled parallel group study. Prior to trial start, volunteers were informed in detail about the study and signed informed consent before they were screened for eligibility. The nutritional study was approved by the appropriate ethics committee of the Landesäerztekammer Baden-Württemberg, Germany and conducted in orientation to ICH-GCP (International Council for Harmonisation's Guideline on Good Clinical Practice) and in compliance with the Declaration of Helsinki. At the beginning and at the end of the 12-week supplementation phase, the volunteers performed an eccentric downhill-walking stress test. Directly before each stress test, immediately after (0 hour) and 3, 24, 48 and 72 hours after the stress test, strength, muscle soreness and biomarker were assessed each. After the first stress test, subjects were randomly assigned to either leucine or the placebo group combined with a special training regimen with Nintendo Wii (Wii Fit Plus and Balance Board). A randomisation scheme was generated using RandList (Tuebingen, Germany). Study products were labelled with the appropriate subject number. Subjects received subject numbers in consecutive order. The study was performed double blindly.

Subjects {#s2b}
--------

Sample size calculation was calculated by GPower V.3.1.2. The sample size of two independent groups (two tailed) in accordance with the literature,[@R15] where the true difference of one repetition maximum in the experimental and control mean was expected to be 16.5±19 kg, was calculated. Statistical calculation resulted in the inclusion of 22 experimental and 22 control subjects to be able to reject the null hypothesis (power=0.8). The alpha error level was defined as 0.05. Considering a dropout rate of 2 volunteers per group, 48 volunteers were enrolled (46 received allocated intervention, and 41 volunteers were analysed), with a 1:1 ratio of men to women (see [figure 1](#F1){ref-type="fig"}).

![Disposition of volunteers.](bmjsem-2016-000156f01){#F1}

Five subjects dropped out during the study, as they were not able to perform the stress test the second time due to injury or joint pain. The subjects sustained the injury independent of the study. In addition, no previous injury (eg, osteoarthritis) was known at the moment of inclusion.

Healthy subjects between 55 and 75 years with a body mass index ranging from 19 to 30 kg/m², with low activity level and low-to-normal skeletal muscle mass (Skeletal Mass Index, determined by Bioelectrical Impedance Analysis measurement during screening) were included in the current trial (see [tables 1 and 2](#T1 T2){ref-type="table"}).

###### 

Inclusion and exclusion criteria for decision of study eligibility

  Inclusion criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Exclusion criteria
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subject is able and willing to sign the informed consent form prior to screening evaluations.Voluntary male and female adults (age 55--75 years)BMI: 19--30 kg/m^2^Non-smoker or smoker with a maximum of 10 cigarettes/daySubject is in good physical and mental health as established by medical history, physical examination, ECG, vital signs, results of biochemistry and haematology.Healthy volunteers with borderline-to-normal muscle mass: Definition of cut-off levels as determined by BIA measurement during screening: women SMI \>22% to ≤31%, men SMI ≤31% to ≤40, 5%.Volunteers have to be non-active athletes. Amateur or professional athletes will not be included in this study.Willing to perform accompanied moderate training according to recommendations from WHO for healthy volunteers during the course of the study.Not anticipating any planned changes in lifestyle regarding activity and nutrition for the duration of the study   Women: known pregnancy, breastfeeding or intention to become pregnant during the studyVolunteers with high-protein diet (\>1--2 g/kg body weight) or additional intake of protein supplements/protein-containing bars or shakesRelevant history or presence of any medical disorder, potentially interfering with this study (eg, volunteers having experienced any cardiovascular events such as infarction, angina, surgical endocoronary intervention or stroke in the last 6 months or volunteers suffering from diabetes)Intake of medications that directly affect parameters of muscle or joint function or inflammation within 2 weeks prior to visit 1 or during the studyFor this study, clinically relevant abnormal laboratory, ECG, vital signs or physical findings at screeningKnown hypersensitivity to the study preparation or to single ingredientsRegular intake of dietary supplements affecting muscle or joint function within 2 weeks prior to visit 1 or during the studyDrug, alcohol and medication abusesKnown HIV infectionKnown acute or chronic hepatitis B and C infectionParticipation in another clinical study within the last 4 weeks and concurrent participation in another clinical studyBlood donation within 4 weeks prior to study start (visit 1) or during the study

BIA, Bioelectrical Impedance Analysis; BMI, Body Mass Index; SMI, Skeletal Mass Index.
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Anthropometric data for men and women allocated to the placebo and the leucine groups

  ----------------------------------------------------------
  Group         Sample\    Age\       BMI\        SMI\
                (n)        (years)    (kg/m^2)^   (%)
  ------------- ---------- ---------- ----------- ----------
  Placebo       Men (12)   60±4       26.7±1.6    35.7±3.0

  ­Women (12)   63±6       26.2±3.4   25.5±2.5    

  Leucine       Men (12)   61±4       25.8±2.1    34.4±2.5

  ­Women (12)   66±6       24.4±2.0   26.3±2.4    
  ----------------------------------------------------------

BMI, body mass index; SMI, Skeletal Mass Index.

Nutritional intervention {#s2c}
------------------------

Study preparations were consumed once per day, delivered in 200 mL water prior to the highest activity (directly before the training was started and on a day without training, in the morning prior to leaving the house). On days prior to visits, study compounds had to be taken 24 hours before the appointment at the study site. During visits, the study preparations were ingested immediately before the stress test. The verum preparation consisted of 3.2 g L-leucine, 0.9 g L-valine, 0.9 g L-isoleucine. The placebo equated to the verum preparation merely without active ingredients.

Training intervention {#s2d}
---------------------

Training was carried out according to WHO recommendations for healthy individuals (three times a week, 30 min each) during the course of the trial and was started after the initial stress test. To ensure standardisation and control of the study, the subjects were instructed to use the Nintendo Wii (Wii Fit Plus and Balance Board) for their training. Each training session was divided into three 10 min sections: aerobic, strength and balance. [Table 3](#T3){ref-type="table"} summarises the training routine, which was changed every month. Volunteers received a training plan with detailed information, including training exercises, duration and intensity. Training intensity was increased weekly (see [table 3](#T3){ref-type="table"}). One week prior to each visit, volunteers were instructed not to exercise with the Nintendo Wii to avoid influences of training on performance during the stress test and further ensure capturing of parameters under the resting state. The training was controlled regularly by extracting the training protocols recorded with the Nintendo Wii.

###### 

Training routine

                                      Week 1--4                      Weeks 5--8                     Weeks 9--12
  ----------------------------------- ------------------------------ ------------------------------ -----------------------
  Aerobic                             Basis step (2--3 min)          Step super (4--5 min)          Step super (4--5 min)
  ­Hula hoop (2 min)                  Obstacle course (2--3 min)     Obstacle course (2--3 min)     
  ­Jogging plus (5--6 min)            Rythm kung-fu (2--3 min)       Jogging plus (2--4 min)        
  Strength                            Lunges (2 min)                 Rowing (1 min)                 Rowing (1 min)
  ­Side steps (2 min)                 Lunges (2 min)                 Lunges (2 min)                 
  ­Single-leg twist (1 min)           Single-leg extension (1 min)   Single-leg extension (1 min)   
  ­Arm and leg lift (1 min)           Torso twist (3 min)            Torso twist (2 min)            
  ­Sideways leg lift 1 min)           Sideways leg lift (1 min)      Lunges (2 min)                 
  ­Torso twist (3 min)                Push-ups (2 min)               Push-ups (2 min)               
  Balance (five games out of seven)   Soccer heading (2 min)                                        
  ­Ski slalom (2 min)                                                                               
  ­Ski jump (2 min)                                                                                 
  ­Balance bubble (2 min)                                                                           
  ­Tightrope walk (2 min)                                                                           
  ­Penguin slide (2 min)                                                                            
  ­Snowboard slalom (2 min)                                                                         

Stress test {#s2e}
-----------

For the evaluation of product-specific effects on muscular fatigue, volunteers had to perform eccentric downhill walking (25% gradient on a treadmill (Woodway Ergo XERG90 specifications) with an additional load of 10% body weight (weight vest). Women had to walk at 4 km/hour, and men had to walk at 5 km/hour. To evaluate the individual performance level, volunteers were asked to walk as long as possible without exceeding a maximum of 40 min at the initial stress test. For the second stress test, the individual protocol from the first stress test was repeated to ensure a comparable physical load for each volunteer. Within the clinical study, a set of up-to-date methods was used, involving analyses of pain, muscle strength and cartilage, inflammation and muscle degeneration markers.

Strength assessment {#s2f}
-------------------

Muscle strength was measured at each point of time by determining the mean out of two isometric maximal voluntary contractions (MVCs) of the left quadriceps femoris muscle. To determine MVCs, a leg extension device was used (David Health Solution, Helsinki, Finland). Each measurement was conducted two times, and the mean value was used. The strength measurement was accomplished by well-trained, strength-measurement-experienced staff and under standardised conditions. The subjects were instructed to gradually contract their muscle to a maximum force during a three-step command. The observer pushed the volunteer verbally until the strength measurement system did not show any augmentation. Usually, the contraction time takes about 4--5 s. With regard to the older collective, no electromyostimulation was used to control for MVC due to ethical aspects.

Muscle soreness {#s2g}
---------------

Volunteers were asked to rate their global muscular pain (muscle soreness) on a 10 cm visual analogue scale. Volunteers rated their muscle soreness before and at each time point after the stress test (0, 3, 24, 48 and 72 hours).

Biomarkers {#s2h}
----------

The test battery included blood sampling to determine serum creatine kinase (CK) as a marker for muscle degradation and C-propeptide of type II procollagen (CP2) and type II collagen collagenase cleavage neoepitope (C2C) to detect potential cartilage synthesis or degradation. All biomarkers were assessed at each point of time (pre stress test, 0, 3, 24, 48 and 72 hours after stress test). Aliquots of serum were taken after centrifugation (3000 g, 4°C, 10 min) 30 min after blood donation. All samples were analysed batchwise for each subject at the end of the study to avoid interassay variations. CK was determined in the routine laboratory (Synlab, Leinfelden-Echterdingen, Germany). To determine CP2 and C2C, a competitive immune assay was used (Ibex Pharmaceutical, Montreal, Canada). The ratio of C2C and CP2 values of \<1 indicates higher cartilage synthesis compared with cartilage degradation. However, values of \>1 reflect predominance of cartilage degradation. The main focus of the study was to observe the influence of the intervention on muscle function and muscle degeneration. The observation of cartilage homeostasis was an incidental question. Therefore, a representative cartilage degradation and synthetis marker was measured. The C2C/CP2 ratio gives a good overview of the homeostasis, as it includes cartilage degradation and synthesis.

Safety assessments {#s2i}
------------------

To assess the safety of the study products, vital signs and blood samples for routine laboratory were determined at all visits. Additionally, adverse events and concomitant medication were documented.

Statistics {#s2j}
----------

Analysis and statistics were done using GraphPad Prism V.5.0 (SPSS and Microsoft Excel). For strength assessment, different periods after the stress test were defined: 0--3 hours was defined as an acute phase, and 24--72 hours was defined as a regeneration phase. To quantify the acute effects before and after intervention, a delta of preintervention to 0 hour and a delta of preintervention to 3 hours was averaged for each group and visit. Out of these acute-strength reductions, a delta of postintervention to preintervention was calculated. The same was done for the regeneration phase time points. An unpaired t-test (differences between groups) on individual parameters was used for statistical analysis if parameters were Gaussian distributed (Shapiro-Wilk test). A Mann-Whitney U test was used in case of non-normal distributions. The same analysis between groups was done for the C2C/CP2 ratio. For changes within a group, one-way repeated measures analyses of variance (rmANOVAs) were assessed. In the case of CK values, extreme outliers were observed. Therefore, data were log transformed prior to analysis. For CK and Visual Analogue Scale, area under the curve (AUC) was calculated and compared between groups using an unpaired t-test or a Mann-Whitney U test, if appropriate. For the C2C/CP2 ratio, the values were normalised to the pretreatment time point.

Results {#s3}
=======

Strength assessment {#s3a}
-------------------

Before, immediately after and 3, 24, 48 and 72 hours after the stress test, MVC of quadriceps femoris muscle of the left leg was assessed to document muscular strength loss induced by downhill walking. Baseline conditions before and after treatment were not significantly different, neither for the placebo nor for the leucine group, indicating the absence of a training effect in MVC due to intervention.

After the stress test, a clear strength reduction induced by downhill walking could be observed, which was true for for the stress test before and after intervention and visible in the placebo and the leucine groups (rmANOVA; p\<0.0001 each). In particular, immediately after and at 3 and 24 hours after the stress test, strength was significantly reduced due to the stress test. In [figure 2](#F2){ref-type="fig"} and [figure 3](#F3){ref-type="fig"}, the baseline corrected knee extension strength at each time point is depicted to show strength reduction due to downhill walking. In particular, in the acute phase (0--3 hours), the regimen leucine plus training was able to buffer the strength loss, induced by downhill walking. [Figure 4](#F4){ref-type="fig"} shows the averaged differences (visit 4 compared with visit 1) of the baseline corrected time points 0--3 hours and 24 --48 hours. This depicts the extent of strength reduction due to intervention for the acute phase after the stress test and the extent of strength reduction for the recovery phase after the stress test. The administration of leucine, plus training, resulted in a reduced loss of strength at 0--3 hours (acute phase) after compared with placebo plus training (p=0.0439; [figure 4](#F4){ref-type="fig"}). For the regeneration phase (24--48 hours), the difference between leucine and placebo was not significant (p=0.2134).

![Baseline corrected strength loss after the eccentric stress test for the placebo group (mean ±95% CI). h, hours; MVC, maximal voluntary contraction. \*\*\*p\<0.001.](bmjsem-2016-000156f02){#F2}

![Baseline corrected strength loss after eccentric stress test for the leucine group (mean ±95% CI). h, hours; MVC, maximal voluntary contraction. \*\*\*p\<0.001.](bmjsem-2016-000156f03){#F3}

![Reduction of strength loss after intervention described as averaged differences (visit 4 compared with visit 1) of the baseline corrected time points 0hours and 24--48 hours. This depicts the extent of strength reduction due to intervention for the acute phase after the stress test and the extent of strength reduction for the recovery phase after the stress test (mean+95% CI). MVC, maximal voluntary contraction. \*p\<0.05.](bmjsem-2016-000156f04){#F4}

Muscle soreness {#s3b}
---------------

Participants reported muscle soreness after the stress test. [Figure 5](#F5){ref-type="fig"} and [figure 6](#F6){ref-type="fig"} show the significant increase in muscle soreness in both groups during the regeneration phase before and after intervention (p\<0.0001, [table 4](#T4){ref-type="table"}). The maximum of muscle soreness could be observed at 48 hours after the stress test. After 72 hours, the pain did not return to baseline. In the placebo and the leucine groups, training effects were observed. Muscle soreness was reduced after intervention. However, no treatment effects could be observed. AUC was not significantly different between groups (p=0.5798, [figure 7](#F7){ref-type="fig"}).

![Muscle soreness after eccentric stress test for the placebo group (mean±95% CI). h, hours; Pre, preintervention; VAS, Visual Analogue Scale. \*\*\*p\<0.001, \*\*p\<0.01. ](bmjsem-2016-000156f05){#F5}

![Muscle soreness after eccentric stress test for the leucine group (mean±95% CI). h, hours; Pre, preintervention; VAS, Visual Analogue Scale. \*\*\*p\<0.001, \*\*p\<0.01. ](bmjsem-2016-000156f06){#F6}

![Reduction of muscle soreness after intervention, described as AUC of the difference after intervention minus before intervention for placebo and leucine (mean±95% CI). AUC, area under the curve, pre--72 h, preintervention to 72 hours.](bmjsem-2016-000156f07){#F7}

###### 

Means (95% CI) for extension strength (MVC), muscle soreness (VAS), C2C to CP2 ratio and logarithmised CK with results of repeated measures ANOVA for the placebo and leucine groups before and after treatment

                                           Before treatment                                                                                                                 
  ------------------ --------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ------------------ ---------
  Group              Variable              Pre                   0 hour                3 hours               24 hours              48 hours              72 hours           p Value
  Placebo            MVC (Nm)              209 (180 to 238)      164 (136 to 192)      172 (140 to 205)      166 (134 to 199)      186 (151 to 222)      199 (163 to 234)   \<0.001
  ­VAS (cm)          0.04 (0.00 to 0.07)   0.57 (0.02 to 1.12)   0.98 (0.30 to 1.66)   4.62 (3.45 to 5.80)   4.76 (3.54 to 5.98)   2.89 (1.78 to 4.00)   \<0.001            
  ­C2C/CP2 (ratio)   1.00 (1.0 to 1.0)     0.93 (0.83 to 1.02)   0.88 (0.79 to 0.97)   0.93 (0.82 to 1.03)   0.96 (0.84 to 1.07)   0.92 (0.72 to 1.11)   0,002              
  ­CK (U/l)          122 (85 to 158)       139 (99 to 178)       210 (154 to 266)      421 (267 to 574)      779 (−173 to 173)     1202 (−875 to 3279)   \<0.001            
  Leucine            MVC (Nm)              204 (176 to 233)      153 (128 to 178)      153 (127 to 178)      159 (132 to 186)      179 (152 to 206)      187 (159 to 215)   \<0.001
  ­VAS (cm)          0.04 (0.01 to 0.07)   0.63 (0.02 to 1.12)   0.88 (0.31 to 1.44)   3.8 (2.70 to 4.89)    5.06 (3.75 to 6.37)   2.61 (1.54 to 3.68)   \<0.001            
  ­C2C/CP2 (ratio)   1.00 (1.0 to 1.0)     0.89 (0.79 to 0.99)   0.84 (0.74 to 0.94)   0.85 (0.77 to 0.94)   0.92 (0.80 to 1.04)   0.96 (0.82 to 1.11)   0,0436             
  ­CK (U/l)          102 (83 to 121)       125 (100 to 149)      210 (158 to 262)      357 (253 to 461)      321 (128 to 515)      820 (−193 to 1833)    \<0.001            
                                           **After treatment**                                                                                                              
  Group              Variable              Pre                   0 hour                3 hours               24 hours              48 hours              72 hours           p Value
  Placebo            MVC (Nm)              219 (185 to 253)      178 (145 to 211)      184 (150 to 218)      192 (158 to 226)      209 (174 to 243)      221 (187 to 256)   \<0.001
  ­VAS (cm)          0.15 (0.01 to 0.29)   0.4 (-0.09 to 0.89)   0.83 (0.34 to 1.32)   2.35 (1.32 to 3.38)   2.9 (1.72 to 4.07)    1.46 (0.77 to 2.16)   \<0.001            
  ­C2C/CP2 (ratio)   1.04 (0.90 to 1.17)   0.84 (0.74 to 0.94)   0.84 (0.75 to 0.94)   0.88 (0.79 to 0.98    0.87 (0.76 to 0.97)   0.92 (0.82 to 1.02)   \<0.001            
  ­CK (U/l)          123 (82 to 163)       126 (88 to 164)       170 (117 to 224)      225 (147 to 304)      159 (113 to 206)      125 (87 to 162)       \<0.001            
  Leucine            MVC (Nm)              200 (170 to 230)      163 (134 to 191)      173 (143 to 203)      180 (149 to 211)      193 (163 to 224)      200 (169 to 231)   \<0.001
  ­VAS (cm)          0.07 (0.01 to 0.12)   0.59 (0.11 to 1.07)   0.74 (0.35 to 1.13)   2.39 (1.45 to 3.32)   2.94 (1.99 to 3.88)   1.26 (0.61 to 1.90)   \<0.001            
  ­C2C/CP2 (ratio)   1.04 (0.9 to 1.17)    0.98 (0.86 to 1.09)   0.91 (0.78 to 1.11)   0.95 (0.78 to 1.09)   0.95 (0.80 to 1.09)   0.93 (0.79 to 1.06)   0,0403             
  ­CK (U/l)          93 (78 to 109)        110 (91 to 130)       141 (113 to 169)      200 (153 to 245)      138 (111 to 164)      109 (87 to 130)       \<0.001            

ANOVA, analysis of variance; C2C, type II collagen collagenase cleavage neoepitope; CK, creatine kinase; CP2, C propeptide of type II procollagen; MVC, maximal voluntary contraction; Pre, preintervention; VAS, Visual Analogue Scale.

Biomarkers {#s3c}
----------

Before and after intervention, CK levels were markedly elevated due to downhill walking (see [table 4](#T4){ref-type="table"}), indicating increased muscle degeneration processes. After intervention, CK was clearly reduced in the placebo and the leucine groups compared with CK levels before intervention ([table 4](#T4){ref-type="table"}). However, no difference in CK reduction (AUC) between intervention groups could be observed.

After the stress test, the C2C/CP2 ratio declined significantly over time in the placebo and the leucine groups before and after intervention (placebo before intervention: p=0.002; placebo after intervention: p\<0.001; leucine before intervention: p=0.0436; leucine after intervention; p=0.0403; [table 4](#T4){ref-type="table"}). In the placebo group, after intervention, the C2C/CP2 ratio was deflected more compared with baseline. In the leucine group, it was vice versa. A decreased deflection could be observed after intervention. To investigate differences between groups, the acute phase and the regeneration phase were analysed separately ([figure 8](#F8){ref-type="fig"}). In the acute phase, the reduction of C2C/CP2 ratio deflection was significantly increased (p=0.038) due to leucine compared with the placebo. In the regeneration phase, the difference between the placebo and leucine was not significant but showed the same tendency.

![Reduction of C2C/CP2 deflection after intervention (mean+95% CI). C2C, type II collagen collagenase cleavage neoepitope; CP2, C propeptide of type II procollagen. \*p\<0.05.](bmjsem-2016-000156f08){#F8}

Discussion {#s4}
==========

The aim of the current study was to examine the effects of a 12-week leucine-rich amino acid supplementation in combination with moderate training in untrained, healthy elderly. The principal findings show that a leucine-rich amino acid supplementation can counteract the negative effects of eccentric exercise. The treatment with leucine-rich amino acids resulted in a reduction of exercise-induced strength loss during the acute phase of regeneration.

Effects of eccentric downhill-walking exercise {#s4a}
----------------------------------------------

The currently used exercise protocol successfully induced muscle damage, shown by a significant strength reduction, appearance of muscle soreness, increase of CK levels and deflection of cartilage homeostasis (C2C/CP2 ratio). The C2C/CP2 ratio represents the effects of downhill walking on cartilage homeostasis. This is of interest to clarify whether changes in strength loss after downhill walking could also influence the loading of joints. This supports the efficacy of loaded downhill walking as a model to induce muscle damage in an untrained, healthy collective of elderly. The model represents a realistic load model close to the everyday life of healthy untrained elderly with normal mobility. The degree of muscle degeneration was comparably high. None of the assessed parameters returned to baseline after 72 hours, which was previously observed in several studies but, in most cases, in a trained collective.[@R16]

In addition to the induced muscle damage, downhill walking clearly disturbed cartilage homeostasis in a healthy collective without joint impairment. It can be hypothesised that due to muscular fatigue, the muscular protection of joints might have been reduced, and the mechanical impact of downhill walking could be directly transferred to the joint complex. In a normal healthy situation, cartilage synthesis and degradation are in balance. If degradation processes are increased, for example, due to high mechanical load, compensatory mechanisms are upregulating synthesis processes to retrieve homeostasis.[@R17] Interestingly, the load induced by downhill walking in the current study triggered the cartilage synthesis to a higher extent than the cartilage degradation. This is in line with the literature for a healthy situation to achieve a steady state.[@R17] [@R18] The stress test used in this study seems to also be suitable to investigate changes of joint metabolism in a healthy situation.

Training effects {#s4b}
----------------

In the current study, moderate training was either combined with a leucine-enriched amino acid treatment or a placebo treatment. As expected, training effects could be documented in both intervention groups. As study products supporting muscle mass or muscle structure are supposed to be mostly beneficial in combination with training, it might be challenging to demonstrate the superiority of the product compared with a placebo. In particular, in an untrained collective, training effects may overlay the supplement effects. The majority of parameters were clearly improved after intervention: muscle soreness after intervention was much lower in both groups, also reflected by decreased muscle degeneration (CK levels). It is worth mentioning that these clear training effects were achieved by training with only moderate intensity, three times a week for 30 min, including aerobic, strength and balance training.

Supplement effects {#s4c}
------------------

The strength loss caused by muscular fatigue was less pronounced after 3 months of supplementation in the treatment group compared with a placebo. The reduction of strength loss was significant between groups for the acute phase within the first 3 hours after downhill walking. This means that acute strength loss induced by the stress protocol was lower after intervention in the treatment group compared with the placebo. It was hypothesised that a better muscular support could protect the joints against overload due to better active joint stability. To evaluate if reduced strength loss after exercise could also protect the joint complex, biomarkers for cartilage homeostasis were determined during the current study. During the current study, a significant lower acute deflection of the C2C/CP2 ratio could be found in the treatment group compared with the placebo. The lower deflection of C2C/CP2 could be interpreted as a lower disturbance of joint homeostasis and a reflection of a higher level of steady state.

Even if it is speculative, it can be assumed that as a consequence of reduced strength loss in the leucine group, the load of the joint complex was reduced, which was supported by less disturbance of the C2C/CP2 ratio.

Conversely, for muscle soreness and CK levels, no supplementation-specific effects could be observed. This is in conflict with previously published data, where BCAA supplementation including leucine showed effectiveness for muscle strength, muscle soreness and CK levels.[@R16] However, in that study, the acute reactions were not measured. Furthermore, the collective consisted of resistance-trained young men, with resistance training twice a week. They proceeded with their normal training during the study without additional training. Therefore, it is likely that training effects were lower in the study of Howatson[@R13] compared with the untrained collective of the current study. Usually, in an untrained collective, even moderate basic training results in high training effects in the first weeks. Presumably, these training effects covered supplement effects for muscle soreness and CK in the presented study.

Strength loss after exercise seems to be less affected by the moderate training. A possible explanation might be the low training intensity of the performed training using the Nintendo Wii. In this case, a higher intensity can only be achieved by a higher repetition number but not with a higher training load. Therefore, the training effects in the current study were predominantly in the area of basic training and strength endurance.

However, functional impairment by eccentric downhill-walking exercise is better tolerated if moderate training is combined with a leucine-enriched amino acid supplementation. Leucine is involved in protein synthesis by influencing the mTOR pathway[@R19] and in decreased protein degradation.[@R20] The effectiveness of BCAA on the reduction of muscle damage has been shown previously.[@R16] The results presented here demonstrate the efficacy of leucine-rich amino acid supplementation in untrained elderly. The combination with moderate training was sufficient to trigger muscle metabolism in such a way that muscle fatigue was less pronounced after eccentric exercise. In addition, the reduction of strength loss may contribute to a better muscular protection of the loaded joint complex. A supplement rich in leucine, combined with moderate training, seems to be a potential intervention in preventing joint overload and muscular fatigue due to eccentric exercise in an older collective. Further studies should clarify if such an intervention could be suitable to prevent from sarcopenia.

**Acknowledgement:** We would like to thank all volunteers who took part in this study.

**Contributors:** CAR, CSchoen, NB, AS and WWA were responsible for study planning, study realisation, data analysis and reporting. CScholz contributed to discussions about the study design prior to the start of the study. CAR wrote the first manuscript, and all other authors critically reviewed the manuscript and contributed with suggestions.

**Funding:** The study was sponsored by Seven Seas. Seven Seas provided the food supplement (study medication) used in the study.

**Competing interests:** The sponsor contributed to discussion about study design and selection of outcome measures prior to study start. During the measurements and data analysis, all data were completely blinded. Measurements and data analysis were executed by CRO BioTeSys GmbH and the Department of Sport and Exercise Science of the University of Stuttgart.

**Ethics approval:** Ethical approval was obtained from the ethical committee of the Landesärztekammer Baden-Württemberg prior to the study of the start.

**Provenance and peer review:** Not commissioned; externally peer reviewed.
